Isracann Biosciences Inc. (CSE:IPOT, XFRA:A2PT0E, OTC:ISCNF) (the “Company”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales, is pleased to advise that it has received the requisite facility design and land use approvals from the Israeli Land Authority preparatory to construction permitting and awarding of building contracts for the proposed phase 1 build-out. Prior to commencement of construction, the Company will require the approval of the Israeli Settlement Commissioner and the Israeli Ministry of Health. These approvals are pending.

Isracann’s plans call for the construction of greenhouse facilities in Nir, Israel. Isracann has finalized engineering drawings from AgroPlan Ltd., an architectural design firm with extensive cannabis experience. The Company solicited and received detailed proposals from multiple cannabis specialty greenhouse construction firms within Israel (and abroad) that specialize in the design, construction and implementation in support of cannabis agricultural projects. Contract awards were predicated upon receipt of land use approvals and will now move ahead expeditiously.


Phase I involves the fabrication of two Isracann facilities totaling up to 115,000 square feet. Each of the greenhouses is based on a 57,500 square foot floorplan with an estimated annual production capacity of 5,750 kg of dried cannabis flower. The facilities will be built to comply with the Israeli Medical Cannabis Good Agricultural Practices (IMC-GAP) and Good Security Practices (IMC-GSP).

Each facility is custom designed to meet or exceed regional environmental needs and is proposed to feature a highly ventilated framework with curtains on all four sides of the vaulted roof configuration. The structural designs are in accordance with Israeli standards (steel structure code 1225, load standards 412/1992 and 414/1982). The preliminary design was approved by the Israeli Ministry of Agriculture & Rural Development. The two phase 1 Isracann greenhouses will have an eight-foot-tall fence surrounding the facilities with an electronic gate for vehicular access for added security. Additionally, a closed-circuit television system will be installed to comply with Israeli Medical Cannabis Agency regulations.

The scope of the project includes a roof design employing polyethylene sheets specifically installed for cannabis cultivation in order to achieve maximum advantage of the unique sunlight exposure in Israel. The cooling and ventilation system utilize three types of fans that help control temperature, humidity and radiation throughout the entire facility. The packing facility includes offices with a built-in kitchen for employees, and a post-harvest area totaling 6,500 square feet featuring dedicated drying, curing and trimming rooms.

Company CEO Darryl Jones states, “This is a milestone for the venture and validates the groundwork, including technical and administrative efforts we have undertaken in recent months to ensure we continue to meet our regulatory targets on schedule. With this approval in place we have met the initial hurdles regarding land use. Now, we can get started with the next step of getting shovels in the ground and begin the business of building our business. We are truly delighted to have achieved so much so quickly, and on behalf of our partners and stakeholders we thank the growing numbers of shareholders who share our vision for the potential growth of the cannabis sector in Israel.”

Re-Pricing and Extension of Warrants

The Company announces that it has received CSE approval for the repricing of 13,835,644 warrants expiring on December 13, 2019, and 139,714 warrants expiring on December 15, 2019 (the “Warrants”). The exercise price will change from $2.25 to $0.51 per share. The Company has also extended the exercise date of the Warrants to January 13, 2020.

The Company also announces that it is extending its agreement, previously announced on November 6th, 2019, for investor relations and marketing with CDMG Inc. to raise public awareness of the Company.

ON BEHALF OF THE BOARD OF DIRECTORS

“Darryl Jones”

Darryl Jones
Chief Executive Officer and President

About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel’s agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.

Click here to connect with Isracann Biosciences Inc. (CSE:IPOT) for an Investor Presentation.

Source

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less